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The tetraspanin CD9 is expressed by all the major subsets of leukocytes (B cells, CD4+ 
T cells, CD8+ T cells, natural killer cells, granulocytes, monocytes and macrophages, 
and immature and mature dendritic cells) and also at a high level by endothelial cells. 
As a typical member of the tetraspanin superfamily, a prominent feature of CD9 is its 
propensity to engage in a multitude of interactions with other tetraspanins as well as 
with different transmembrane and intracellular proteins within the context of defined 
membranal domains termed tetraspanin-enriched microdomains (TEMs). Through these 
associations, CD9 influences many cellular activities in the different subtypes of leuko-
cytes and in endothelial cells, including intracellular signaling, proliferation, activation, 
survival, migration, invasion, adhesion, and diapedesis. Several excellent reviews have 
already covered the topic of how tetraspanins, including CD9, regulate these cellular 
processes in the different cells of the immune system. In this mini-review, however, we 
will focus particularly on describing and discussing the regulatory effects exerted by CD9 
on different adhesion molecules that play pivotal roles in the physiology of leukocytes 
and endothelial cells, with a particular emphasis in the regulation of adhesion molecules 
of the integrin and immunoglobulin superfamilies.
Keywords: CD9, tetraspanins, integrins, iCAM1, activated leukocyte cell adhesion molecule, ADAM17, lymphocyte 
function-associated antigen 1, very late activation antigen 4
inTRODUCTiOn
CD9, or Tspan 29 in the systematic nomenclature, is a 21–24 kDa member of the tetraspanin protein 
family. Tetraspanins are structurally characterized by containing four transmembrane domains, 
which delimit a small extracellular loop (known as SEL or EC1), a large extracellular loop (termed 
LEL or EC2), and short intracellular N- and C-terminal tails. Within the LEL domain five α-helices 
(A-E) can be distinguished, with helices A, B, and E defining a region well conserved among diffe-
rent members (“constant region”) that is involved in tetraspanin dimerization and oligomerization, 
whereas helices C and D define the “variable region” of the LEL, involved in most lateral inter-
actions of tetraspanins with other membrane proteins. The presence of a CCG motif after the B 
Abbreviations: ADAM, a disintegrin and metalloproteinase; ALCAM, activated leukocyte cell adhesion molecule; BBB, 
blood–brain barrier; CAMs, cell adhesion molecules; CNS, central nervous system; cSMAC, central supramolecular activa-
tion cluster; DCs, dendritic cells; EAPs, endothelial adhesive platforms; ER, endoplasmic reticulum; ICAM-1, intercellular 
adhesion molecule 1; Ig-SF, immunoglobulin superfamily; IL-2, interleukin-2; IS, immune synapse; LDL, low density lipopro-
teins; LFA-1, lymphocyte function-associated antigen 1; LPS, lipopolysaccharide; mAb, monoclonal antibody; MMP, matrix 
metalloproteinase; NK, natural killer cells; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; pSMAC, 
peripheral supramolecular activation cluster; TEMs, tetraspanin-enriched microdomains; TLR4, toll like receptor-4; TNF-α, 
tumor necrosis factor-alpha; VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late activation antigen 4.
TABLe 1 | List of molecules reported to associate with CD9.
CD9-associated molecules Other associated 
tetraspanins
Reference
Adhesion molecules
integrins
α1β1 (12)
α2β1 CD151 (13, 14)
α3β1 CD63, CD81, CD82, 
CD151, NAG-2, Co-029
(13, 14)
α4β1 [very late activation antigen 4 
(VLA-4)]
CD53, CD81, CD82, 
CD151
(15, 16)
α5β1 (VLA-5) CD151 (16)
α6β1 CD63, CD81, CD82, 
CD151, NAG-2, Co-029
(15, 17)
α7β1 CD151 (18)
αIIbβ3 CD151 (19, 20)
α6β4 CD151 (13)
αLβ2 (lymphocyte function-associated 
antigen 1)
CD81, CD82 (21–23)
immunoglobulin-SF members
Intercellular adhesion molecule 1 (CD54) CD151 (24, 25)
EpCAM (CD326) Co-29, Tspan8, D6.1A (26)
B-CAM/Lu (CD239) (27)
Activated leukocyte cell adhesion 
molecule (cD166)
(28, 29)
Vascular cell adhesion molecule-1 
(CD106)
CD151 (24)
Other adhesion receptors
CD42 (20, 30)
CD44 Co-29, Tspan8, D6.1A (13)
CD47 (20)
Claudin-1 (31)
Syndecan (13)
immune system molecules
HLA-DR CD153, CD81, CD82 (15)
CD2 CD53 (32)
CD3 CD81, CD82 (33)
CD4 CD81, CD82 (33)
CD5 (33)
CD19 CD81 (34)
CD46 (12)
Growth factors
Pro-TGF-α (35)
Pro-HB-EGF (36)
Signaling molecules
CD117 CD63, CD81 (37)
GPCR56 CD81 (38)
PI4K CD81, CD151, CD63 (39)
PKC CD53, CD81, CD82, 
CD151
(27, 40)
Other proteins
ADAM2 CD81 (41)
ADAM10 CD81, CD82 (42, 43)
ADAM17 (42, 44)
CD36 (45)
CD26 (DPPIV) (27, 46)
CD224 CD37, CD81, CD53, 
CD82
(27)
CTL1/CD92 (27)
CTL2 (27)
EWI-2 CD63, CD81, CD82, 
CD151
(47)
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helix in the LEL domain, with its two cys teines engaged in the 
formation of intradomain disulfide bonds with other conserved 
cysteines, membrane-proximal palmitoylations, and hydrophilic 
residues within transmembrane domains are also defining 
features of tetraspanin members. Tetraspanins are glycoproteins 
which generally contain several N-glycosylation sites in the LEL 
domain (1), and in this regard, CD9 is peculiar as it contains only 
one N-glycosylation site that is located in its SEL domain (2).
CD9 shows a wide cellular and tissue distribution and was 
initially identified as a lymphohematopoietic marker (3) and 
then implicated in a range of cellular functions, including motility, 
proliferation, differentiation, fusion, and adhesion [reviewed in 
Ref. (1, 4–6)]. Not surprinsingly, given its involvement in such a 
range of crucial cell activities, CD9 plays a major role in critical 
physiological and pathological processes, including sperm–egg 
fusion, neurite outgrowth, myotube formation, viral infections, 
tumorigenicity, and metastasis [reviewed in Ref. (7–9)]. As for 
other members of the tetraspanin family, the biological functions 
of CD9 greatly depend on the multitude of dynamic interactions 
that this molecule is able to establish with other transmembrane 
and cytoplasmic proteins within the context of a specific type of 
membrane domains, called tetraspanin-enriched microdomains 
(TEMs) (10, 11). CD9 in TEMs can thus affect, either directly or 
indirectly, the activity of numerous transmembrane and intra-
cellular proteins such as metalloproteinases and other enzymes, 
ion channels, receptors for growth factors, cytokines and che-
mokines, transporters, signaling transducers, and cytoskeletal 
linkers (Table 1). CD9 can potentially alter the activity of these 
molecules through different mechanisms including their selec- 
tive confinement in TEMs or segregation into separate micro-
domain compartments, which would hinder their access to their 
cognate substrates or binding of their extracellular or intracellular 
ligands (10, 11).
It is striking that the basal expression of CD9 in the major 
types of leukocytes from freshly drawn blood [monocytes, nat-
ural killer (NK) cells, B cells, CD8+ T cells, and CD4+ T cells] is 
usually low (49, 50). However, its expression in these leukocyte 
subpopulations increases following their culture, being par-
ticularly high in monocytes (8, 49, 50). Likewise, CD9 is also 
clearly detected in activated lymphoblasts derived from PHA/
interleukin-2-stimulated PBMCs (21). CD9 is also expressed 
by the different subsets of human and murine dendritic cells 
(DCs), with the exception of mouse plasmacytoid DCs (51). In 
contrast to the relatively low expression on resting leukocytes, 
the expression of CD9 is particularly high on endothelial cells 
(52), in keeping with the crucial role this tetraspanin plays in 
regulating the firm adhesion and transendothelial migration of 
leukocytes (24, 25).
Several excellent reviews have already covered the topic of 
how tetraspanins, including CD9, participate in the regulation of 
specific functions in different cells of the immune system (4, 8, 
53, 54). In this review, however, we will focus particularly on 
discussing the regulatory effects exerted by CD9 on different 
adhesion molecules that play pivotal roles in the physiology of 
leukocytes and endothelial cells, with a particular emphasis in 
the regulation of adhesion molecules of the integrin and immu-
noglobulin superfamilies. (Continued)
CD9-associated molecules Other associated 
tetraspanins
Reference
EWI-F CD81 (48)
Hem-1 (27)
TADG-15 (27)
Syntaxins 3 and 4A (27)
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CD9 ReGULATeS ADHeSiOn 
MOLeCULeS AT THe iMMUne SYnAPSe 
(iS) AnD T LYMPHOCYTe ACTivATiOn
Recognition of antigenic-peptides bound to MCH-I and MCH-II 
molecules on the surface of antigen presenting cells (APCs) is 
essential for activation of CD8+ and CD4+ T cells, respectively, and 
triggers the initiation of T cell-mediated immune responses. This 
process requires the establishment of a dynamic structure at the 
APC-T cell contact area, termed as IS. In its mature form, the IS 
contains a clearly distinguishable central region (cSMAC), where 
clusters of TcR/CD3, costimulatory and signaling molecules 
concentrate, and a peripheral region (pSMAC) highly enriched 
in integrins and other adhesion molecules (55, 56). The establish-
ment of IS proceeds through a series of spatiotemporal segregated 
events, including the initial scanning of antigen peptide-loaded 
MHC molecules, the specific recognition of antigen-loaded MHC, 
and signaling by the TcR/CD3 complex and stabilization of the IS. 
The interaction of different adhesion receptors on either side of 
the IS (i.e., on the APC or on the T cell) with their specific ligands 
on the opposing side is essential during the initial scanning and 
stabilization of the IS. In particular, interactions of integrin 
lymphocyte function-associated antigen 1 (LFA-1) (αLβ2) on the 
T cell with its ligands intercellular adhesion molecule 1 (ICAM-1) 
and ICAM-3 on the APC surface are crucial for IS formation 
and stabilization. During the initial scanning of MHC-peptide 
complexes on the surface of APCs, the affinity of T cell LFA-1 for 
its ligands is low/intermediate, but inside-out signaling triggered 
from the TcR/CD3 complex upon recognition of the cognate 
MHC-peptide induces the high-affinity state of this integrin, lead-
ing to strong ligand binding and stabilization of the IS (57, 58). 
TcR and LFA-1 molecules on immune cells are preorganized in 
nanoclusters that coalesce into larger aggregates following ligand 
binding (59–62). CD9 has been shown to engage through its LEL 
domain in direct interactions with LFA-1 on the surface of differ-
ent types of leukocytes, including T lymphocytes and monocyte/
macrophage-like cells (21). Through its association with LFA-1, 
CD9 controls the state of aggregation and adhesive capacity of 
this integrin. Through the use of different strategies, such as 
monoclonal antibody (mAbs) specific for CD9, as well as genetic 
approaches based on its silencing or neoexpression, it was dem-
onstrated that CD9 exerts a negative regulation on the adhesive 
capacity of LFA-1. The mechanism involved in this inhibitory 
effect of CD9 on LFA-1 activity does not rely upon changes in 
the integrin affinity state, as inferred from the unaltered expres-
sion of the activation-reporter 24 epitope (21). These findings 
concur with the observation that talin relocalization, which is 
required for the induction of conformational changes in LFA-1 
and acquisition of increased affinity through inside-out signaling 
[reviewed in Ref. (63)], is not altered in T cells with silenced CD9 
and CD151 (64). Thus, the negative regulation exerted by CD9 
on the adhesive capacity of LFA-1 is rather related to alterations 
in its state of aggregation and the control of its binding valency 
(avidity). Interestingly, confocal and TIRF microscopy analyses 
showed that expression of CD9 in lymphocytic and monocytic 
cells induces LFA-1 molecules to become organized in a larger 
number of clusters but individually displaying a smaller size, 
which would account for the reduced integrin adhesive capacity 
(21) (Figure 1A). The association of LFA-1 with the actin cyto-
skeleton has long been known to control the avidity of this 
integrin through regulation of its dynamic reorganization into 
microclusters (65). Thus, although the exact mechanism by which 
CD9 alters the state of aggregation of LFA-1 molecules has not 
been resolved, it likely relies upon the linkage of this tetraspanin 
with the microfilaments of the actin cytoskeleton through the 
Ezrin–Radixin–Moesin (ERM) proteins (66).
In addition to LFA-1, VLA-4 (α4β1) is another integrin pre-
dominantly expressed on hematopoietic cells, which also concen-
trates at the pSMAC playing a role in the stabilization of the IS 
and in T cell co-stimulation, though the precise ligand for this 
integrin on the APC is still unknown (67). The two classic ligands 
of integrin α4β1, alternatively spliced fibronectin and VCAM-1, 
are not expressed on APCs. Alternative ligands of this integrin 
are members of the junctional adhesion molecules (JAM) family, 
but it has not been demonstrated so far whether these molecules 
play a role in the IS. Contrary to CD81, which strongly colocal-
izes with CD3 and contributes to cSMAC formation, becoming 
segregated from LFA-1 which is mainly found at the pSMAC, 
CD9 (along with CD151) shows less colocalization with CD3, 
indicating that it is not involved in the reorganization and clust-
ering of CD3 at the IS (64). In contrast, CD9 does associate with 
integrin α4β1 on T cells and drives both the accumulation of the 
high-affinity form of this integrin at the IS and the subsequent 
downstream signaling (64). CD9 (or CD151) silencing results 
in diminished relocalization of integrin α4β1 to the IS, reduced 
accumulation of high-affinity β1 integrins at the cell–cell contact 
area, and decreased downstream integrin signaling.
Besides their adhesive function, integrins also work as efficient 
bidirectional signaling molecules (68). In T cells, LFA-1 costimu-
lation lowers the TcR-mediated activation threshold (69, 70). 
Similarly, ligation of integrin α4β1 also provides costimulatory 
signaling (71). Downstream signaling from these adhesion recep-
tors is mediated through interactions with a number of adaptor 
and signaling molecules (72, 73), whose activity, location, and 
aggregation may be regulated by tetraspanins through their selec- 
tive inclusion in, or exclusion from, specific TEMs. CD9 and 
CD151 have been shown to increase integrin-dependent ERK1/2 
signaling, and the knockdown of these tetraspanins reduces the 
phosphorylation of focal adhesion kinase (FAK) and ERK1/2 
integrin downstream targets and impairs the enrichment of 
phosphorylated FAK at the IS (64).
Activated leukocyte cell adhesion molecule (ALCAM) or 
CD166 is a member of the immunoglobulin superfamily of 
CAMs that can engage in homophilic (ALCAM–ALCAM) as well 
TABLe 1 | Continued
FiGURe 1 | Functional regulation exerted by CD9 on the activity of some immune system adhesion molecules. (A) CD9 regulates ICAM and lymphocyte function-
associated antigen 1 (LFA-1) at the immune synapse (IS). Interactions between LFA-1 on the T cell, and its ligand intercellular adhesion molecule 1 (ICAM-1) on the 
APC surface, take place at the peripheral area of the IS (pSMAC) and are crucial for IS formation and stabilization. The tetraspanin CD9 plays an important role in the 
IS in two different ways: (1) Through its association with LFA-1 on the T cell, CD9 controls the state of aggregation and adhesive capacity of this integrin. 
Neoexpression/overexpresion of CD9 reduces the integrin adhesive capacity by generating a larger number of clusters of LFA-1 molecules that individually display a 
smaller size. (2) On the APC surface CD9 recruits ICAM-1 into TEMs, thus increasing its adhesive capacity. (B) CD9 regulates leukocyte firm adhesion on endothelial 
cells. The multi-step paradigm of the leukocyte extravasation cascade includes the initial tethering and rolling of the leukocyte on the endothelial surface, followed by 
the firm adhesion step and transmigration either between two endothelial cells or through the body of an endothelial cell. The firm adhesion step is mediated by the 
high-affinity interaction of leukocyte integrins LFA-1 (αLβ2) and Mac-1 (αMβ2) with their endothelial counter-receptor ICAM-1, and of integrin VLA-4 (α4β1) with its 
endothelial ligand VCAM-1. ICAM-1 and VCAM-1 are preorganized in endothelial adhesive platforms (EAPs), through their association with CD9 and CD151 
respectively. After leukocyte binding, EAPs evolve into three-dimensional docking structures that emanate from the endothelial surface and embrace the leukocyte. 
(C) CD9 affects the shedding of leukocyte adhesion molecules mediated by ADAM17. The recruitment of ADAM17 into CD9-organized TEMs (low panel), following 
the overexpression or neoexpression of this tetraspanin, exerts a negative regulation on the sheddase activity of ADAM17 against different substrates on leukocytic 
cells, including activated leukocyte cell adhesion molecule (ALCAM). This negative regulation on ADAM17 activity accounts for an increased expression of ALCAM 
on the cell surface. Additionally, CD9 also induces the aggregation of ALCAM and the concomitant increase in its avidity. Therefore, CD9 augments ALCAM-
mediated cell–cell adhesion through this dual mechanism.
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as heterophilic (ALCAM–CD6) interactions. ALCAM-mediated 
adhesion is crucial in different physiological and pathological 
situations, with particular relevance in immune responses, col-
lective cell mig ration, cancer metastasis, neuronal development, 
and leukocyte migration across blood–brain barrier (BBB) in 
multiple sclerosis and autoimmune encephalomyelitis. ALCAM 
on APCs engages in heterophilic interactions with CD6 on 
T cells, with both molecules becoming redistributed to the IS in 
5Reyes et al. CD9 Regulates Immune Cell Adhesion
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an antigen-dependent manner, which have been shown to play an 
important role in the formation and stabilization of the IS (74). 
They also provide costimulatory signals and thus contribute to 
T  cell activation and proliferation (75–77). ALCAM-mediated 
APC-T cell adhesion requires upregulation of ALCAM avidity for 
CD6, which is brought about by the aggregation of ALCAM mol-
ecules on the cell surface, a process that is in turn controlled by their 
dynamic association with the actin cytoskeleton. Such dynamic 
linkage with the actin cytoskeleton takes place through the interac-
tion of a C-terminal KTEA PDZ-binding motif and a membrane-
proximal positively charged stretch in ALCAM’s cytoplasmic 
tail, with the adaptor proteins syntenin-1 and the ERM protein 
ezrin, respectively (28, 78).
In this context, CD9 has been shown to play an important role 
in the regulation of ALCAM-mediated cell adhesion and T cell 
activation. On leukocytes, CD9 acts as a scaffold in ALCAM-
containing TEMs, engaging in direct lateral interactions through 
its LEL domain with the extracellular region of ALCAM, 
therefore, upregulating its adhesive capacity and co-stimulation 
in T cells through its ligand CD6 (29). Importantly, this enhance-
ment of ALCAM avidity and functional activity induced by CD9 
is mediated by a dual mechanism involving, on the one hand, 
augmented clustering of ALCAM molecules and, on the other 
hand, upregulation of ALCAM surface expression due to the 
inhibition of ADAM17/TACE sheddase activity (the latter will 
be discussed below) (Figure  1C). As CD9 has been shown to 
be part of TEMs that contain a number of proteins directly lin-
ked to ERM proteins (66), this tetraspanin could contribute an 
additional level of regulation to the dynamic association with the 
actin cytoskeleton that ultimately controls ALCAM avidity and 
costimulatory capacity.
enDOTHeLiAL CD9 ReGULATeS 
LeUKOCYTe ADHeSiOn, 
eXTRAvASATiOn, AnD inFLAMMATiOn
Migration across the endothelial cell layer that lines the inner 
surface of blood vessels is required for leukocyte recirculation 
during immune surveillance and their accumulation at sites of 
tissue infection and inflammation. Circulating leukocytes exit the 
blood vessels at certain preferred sites, such as the high endo-
thelial venules of secondary lymphoid organs or the postcapil- 
lary venules at sites of inflammation. Leukocyte transendothelial 
migration proceeds through a series of steps which are mediated 
by a set of complex and sequential interactions between adhesion 
receptors and counter-receptors expressed on the leukocyte and 
the endothelial apical surface. This sequence of events represents 
the multi-step paradigm of the leukocyte extravasation cascade 
(79–81). These steps include the initial tethering and rolling of 
the leukocyte on the endothelial surface, followed by the firm 
adhesion, subsequent crawling on the endothelial apical surface 
in search for an appropriate exit site and the actual transmigra-
tion either between two endothelial cells (paracellular route) or 
through the body of an endothelial cell (transcellular route) and 
finally, leukocyte migration in the interstitial tissue following 
specific chemotactic cues. Specifically, the step of firm leukocyte 
adhesion to the endothelium is fundamentally mediated by the 
high-affinity interaction of leukocyte integrins, LFA-1 (αLβ2) and 
Mac-1 (αMβ2), with their endothelial counter-receptor ICAM-1, 
and of integrin VLA-4 (α4β1) with its endothelial ligand VCAM-1. 
These high-affinity interactions require the activation of integrins 
in response to intracellular signals triggered upon recognition by 
leukocyte chemokine receptors of chemokines immobilized on 
heparan sulfate proteoglycans on the endothelial apical surface.
Vascular endothelium plays an active role in transendothelial 
leukocyte migration by controlling the expression level and 
organization of adhesive molecules. Following exposure to proin-
flammatory cytokines (such as TNF-α and IL-1β), an increase in 
the expression of E- and P-selectins (main mediators of leukocyte 
tethering and rolling steps) and integrin ligands ICAM-1 and 
VCAM-1 is induced on the apical surface of endothelial cells, 
thus facilitating leukocyte adhesion to the endothelium and their 
subsequent transmigration. Interestingly, ICAM-1 and VCAM-1 
on the endothelial surfaces are preorganized in adhesive clusters, 
so-called endothelial adhesive platforms (EAPs), by their inclu-
sion in tetraspanin nanoplatforms through their association with 
CD9 and CD151 (24, 25). Analysis by FLIP-FRET microscopy 
evidenced that specificity exists in these associations, with 
CD9 preferentially associating with ICAM-1 whereas CD151 
preferentially associates with VCAM-1 (24) (Figure 1B). Upon 
leukocyte binding, EAPs evolve into three-dimensional docking 
structures formed by elongated microvilli and long filopodia 
that emanate from the endothelial surface and embrace the 
adherent leukocytes, preventing their detachment under physi-
ological hemodynamic flow conditions. The formation of these 
structures requires not only the tetraspanin-mediated clustering 
of ICAM-1 and VCAM-1, but also an active participation of 
the actin cytoskeleton and associated proteins, such as ERMs 
(ezrin–radixin–moesin), α-actinin, vinculin, filamin, cortactin, 
and vasodilator-stimulated phosphoprotein (VASP), as well as 
signaling molecules like Rho A/ROCK, MLCK, src, pyk-2, and 
PIP2 (82–84). Importantly, in the absence of CD9 the formation 
of microvilli required for the development of full docking 
structures is inhibited, crucially underlying the relevance of 
this particular tetraspanin in regulating the firm adhesion and 
transendothelial migration of leukocytes (85).
ALCAM is also abundantly expressed on endothelial cells 
in central nervous system (CNS) and has been shown to par-
ticipate in the formation of docking structures (or transmigratory 
cups) required for leukocyte diapedesis (86). Interestingly, unlike 
ICAM-1 and VCAM-1, ALCAM mediates the transmigration 
of both lymphoid and myeloid leukocytes (86), and seems to be 
particularly relevant in the extravasation of monocytes rather 
than T cells across the BBB (87). Blockade of ALCAM reduced 
the transmigration of CD4+ lymphocytes and monocytes across 
the BBB and reduced the severity and delayed the time of onset of 
experimental autoimmune encephalomyelitis in animal models, 
highlighting the potential usefulness of ALCAM as a therapeutic 
target in multiple sclerosis (86). ALCAM has also been found to 
associate with tight junction molecules that maintain BBB integ-
rity (88). The interaction of CD9 with ALCAM on endothelial 
cells has not been as yet properly explored, but considering that 
ALCAM participates in the formation of docking structures and 
6Reyes et al. CD9 Regulates Immune Cell Adhesion
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what has been reported on leukocytic cells (29), it is likely that 
CD9 could also crucially regulate both the organization and the 
level of expression of ALCAM molecules on the CNS endothe-
lium, critically controlling the transmigration of lymphocytes 
and monocytes across the BBB.
CD9 ReGULATeS THe SHeDDinG OF 
LeUKOCYTe ADHeSiOn MOLeCULeS 
MeDiATeD BY ADAM10 AnD ADAM17 
MeTALLOPROTeASeS
Another important mechanism by which CD9 is capable to 
influence the activity of adhesion molecules with relevance in 
the immune system is through the modulation of ADAM10 and 
ADAM17 metalloproteinases. These two closely related members 
of the a disintegrin and metalloproteinase (ADAM) family are 
key enzymes responsible for the cleavage and release from the cell 
surface of the ectodomains of a large variety of transmembrane 
proteins, a process known as ectodomain shedding. Through 
this process, cells can rapidly alter their surface phenotype by 
releasing a variety of soluble protein ectodomains that can sub-
sequently trigger autocrine, juxtacrine, paracrine, or endocrine 
cellular signaling and responses in specific target cells. The list of 
identified protein substrates that can be shed either by ADAM10 
or by ADAM17 has kept on growing over recent years and cur-
rently comprises over a hundred different cell surface proteins, 
including growth factors, cytokines, many types of receptors, and 
numerous cell adhesion molecules (CAMs). Among the CAMs 
shed by ADAM10 or ADAM17 there are members of the immu-
noglobulin (ICAM-1, L1-CAM, Ep-CAM, VCAM-1, ALCAM, 
and JAM-A), integrin, cadherin, and selectin families as well as 
other adhesion receptors like CD44 (89–91). Many of the protein 
substrates of these two proteases are shared, indicating that 
their function may sometimes be complementary or redundant, 
but the mechanisms that selectively regulate their individual 
activities and substrate preference are still poorly understood. 
Regulation of ADAMs’ shedding activities can be achieved at 
different levels, impacting upon their intracellular trafficking 
and maturation, metalloprotease activity, and accessibility of 
substrates [as reviewed in Ref. (92, 93)].
Tetraspanins are emerging as important regulators of ADAMs’ 
shedding activities. By dynamically regulating their inclusion in, 
or exclusion from specific TEMs, tetraspanins are shown to influ-
ence the relative localization of ADAMs and their substrates on 
the plasma membrane, thus exerting crucial regulatory effects on 
their sheddase activity [reviewed in Ref. (42, 94)].
CD9 and other tetraspanins (including CD53, CD81, CD82, 
and CD151), have been reported to associate with ADAM10 
under mild solubilization conditions. Additionally, antibody 
engagement of CD81, CD82, or CD9 did indeed stimulate 
ADAM10-dependent shedding of its substrates TNF-α and EGF 
(43). However, subsequent experiments using more stringent 
detergent conditions indicated that these tetraspanins do not 
associate directly with ADAM10 (95). Such interactions, instead, 
seem to be mediated through a distinct subfamily of tetraspanins 
(TspanC8), whose specific and direct association with ADAM10 
regulates its exit from the ER, enzymatic maturation, intracellular 
traffi cking, subcellular localization, and its metalloprotease activ-
ity against different cell surface protein substrates (94, 96, 97).
Importantly, CD9 is the only tetraspanin that has so far been 
reported to associate directly with ADAM17 on the surface of 
leukocytes and endothelial cells. This direct association was 
demonstrated by image and biochemical techniques, including 
confocal microscopy, proximity ligation, co-immunoprecipita-
tion, covalent crosslinking, and pull-down assays. Heterologous 
expression/overexpression of CD9 or treatment with agonist 
CD9-specific antibodies inhibited ADAM17-mediated shed-
ding of different substrates from leukocytic cells, including 
TNF-α and the adhesion molecules ICAM-1 and ALCAM/
CD166. Thus, while anti-CD81 mAbs enhanced the release of 
TNF-α mediated by ADAM10 (43), anti-CD9 mAbs regulated 
negatively the stimulated release of that proinflammatory 
cytokine mediated by the closely related sheddase ADAM17 (44). 
Additionally, CD9 knockdown increased ADAM17-mediated 
shedding of its substrates (29, 44). CD9-mediated inhibition of 
ALCAM shedding by ADAM17 resulted in increased ALCAM 
levels on the cell surface and augmented ALCAM-mediated cell 
adhesion (29) (Figure 1C). These findings were later confirmed 
for additional ADAM-17 substrates, like LR11 (SorLa), a mem-
ber of the low density lipoprotein receptor family which binds 
ApoE and has a key role in cell migration, adhesion, and drug 
resistance (98).
COnCLUDinG ReMARKS
CD9 is emerging as an important regulatory molecule that con-
trols the expression and activity of different adhesion molecules 
of crucial importance in the immune system. At the IS, CD9 on 
the T  cell side regulates the clustering and adhesive activity of 
integrins LFA-1 (αLβ1) and VLA-4 (α4β1), whereas on the APC 
side, CD9 regulates the expression of ALCAM/CD166 and the 
avidity of its interaction with CD6. Through the control exerted 
by CD9 on the expression and/or activity of these adhesive recep-
tors, this tetraspanin regulates the stabilization of the IS and the 
subsequent activation of T lymphocytes.
On activated endothelial cells exposed to inflammatory 
cytokines, tetraspanins CD9 and CD151 play a crucial role in 
the step of firm leukocyte adhesion by arranging endothelial 
ICAM-1 and VCAM-1 in preorganized adhesive clusters, called 
EAPs. Upon leukocyte binding to the luminal endothelial surface, 
EAPs evolve into docking structures that embrace the leukocytes, 
preventing their detachment under flow conditions.
CD9 is the only tetraspanin that has been shown to associate 
directly with ADAM17 on leukocytes and endothelial cells. Through 
this direct interaction with ADAM17, CD9 inhibits the sheddase 
activity of this metalloproteinase against its substrates, thus regu-
lating the balance between the membrane and soluble forms of 
crucial adhesion molecules, such as ICAM-1 and ALCAM, which 
are key in the processes of leukocyte extravasation and recruit-
ment into inflamed tissues and stabi lization of the IS.
These important regulatory effects exerted by CD9 on the 
activity of adhesion molecules with relevance in the immune 
system are summarized in the three panels of Figure 1.
7Reyes et al. CD9 Regulates Immune Cell Adhesion
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 863
AUTHOR COnTRiBUTiOnS
CC conceived and wrote the manuscript. RR and CC designed 
the figures. BC, YM-P, and RR commented and edited 
the manuscript. All authors read and approved the final 
manuscript.
ACKnOwLeDGMenTS
Authors thank Dr. María Yáñez-Mó for critical reading of the 
manuscript and helpful suggestions.
FUnDinG
This work has been supported by grant SAF2016-77096-R from 
Ministerio Español de Economía y Competitividad (MINECO), 
awarded to CC. BC salary has been supported by a grant from 
Fundación Ramón Areces (Ayudas a la Investigación en Ciencias 
de la Vida y de la Materia, 2014) and by the grant SAF2016-
77096-R from MINECO. We acknowledge support of the 
publication fee by the CSIC Open Access Publication Support 
Initiative through its Unit of Information Resources for Research 
(URICI).
ReFeRenCeS
1. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci (2001) 58:1189–205. 
doi:10.1007/PL00000933 
2. Boucheix C, Benoit P, Frachet P, Billard M, Worthington RE, Gagnon J, et al. 
Molecular cloning of the CD9 antigen. A new family of cell surface proteins. 
J Biol Chem (1991) 266:117–22. 
3. Boucheix C, Benoit P. CD9 antigen: will platelet physiology help to explain 
the function of a surface molecule during hemopoietic differentiation? Nouv 
Rev Fr Hematol (1988) 30:201–2. 
4. Levy S, Shoham T. The tetraspanin web modulates immune-signalling com-
plexes. Nat Rev Immunol (2005) 5:136–48. doi:10.1038/nri1548 
5. Hemler ME. Specific tetraspanin functions. J Cell Biol (2001) 155:1103–7. 
doi:10.1083/jcb.200108061 
6. Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev 
Cancer (2013) 14:49–60. doi:10.1038/nrc3640 
7. Ovalle S, Gutiérrez-López MD, Olmo N, Turnay J, Lizarbe MA, Majano P, 
et  al. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of 
human colon carcinoma cells. Int J Cancer (2007) 121:2140–52. doi:10.1002/
ijc.22902 
8. Wright MD, Moseley GW, van Spriel AB. Tetraspanin microdomains in 
immune cell signalling and malignant disease. Tissue Antigens (2004) 64: 
533–42. doi:10.1111/j.1399-0039.2004.00321.x 
9. Hemler ME. Targeting of tetraspanin proteins – potential benefits and stra-
tegies. Nat Rev Drug Discov (2008) 7:747–58. doi:10.1038/nrd2659 
10. Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C, Rubinstein E. Lateral 
organization of membrane proteins: tetraspanins spin their web. Biochem J 
(2009) 420:133–54. doi:10.1042/BJ20082422 
11. Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez- 
Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell 
plasma membranes. Trends Cell Biol (2009) 19:434–46. doi:10.1016/j.tcb.2009. 
06.004 
12. Lozahic S, Christiansen D, Manié S, Gerlier D, Billard M, Boucheix C, 
et  al. CD46 (membrane cofactor protein) associates with multiple beta1 
integrins and tetraspans. Eur J Immunol (2000) 30:900–7. doi:10.1002/1521- 
4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X 
13. Jones PH, Bishop LA, Watt FM. Functional significance of CD9 associ- 
ation with beta 1 integrins in human epidermal keratinocytes. Cell Adhes 
Commun (1996) 4:297–305. doi:10.3109/15419069609010773 
14. Scherberich A, Moog S, Haan-Archipoff G, Azorsa DO, Lanza F, Beretz A. 
Tetraspanin CD9 is associated with very late-acting integrins in human vas- 
cular smooth muscle cells and modulates collagen matrix reorganization. 
Arterioscler Thromb Vasc Biol (1998) 18:1691–7. doi:10.1161/01.ATV.18. 
11.1691 
15. Rubinstein E, Le Naour F, Lagaudrière-Gesbert C, Billard M, Conjeaud H, 
Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface 
tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 
(1996) 26:2657–65. doi:10.1002/eji.1830261117 
16. Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C. CD9 antigen 
is an accessory subunit of the VLA integrin complexes. Eur J Immunol  
(1994) 24:3005–13. doi:10.1002/eji.1830241213 
17. Berditchevski F, Zutter MM, Hemler ME. Characterization of novel complexes 
on the cell surface between integrins and proteins with 4 transmembrane 
domains (TM4 proteins). Mol Biol Cell (1996) 7:193–207. doi:10.1091/
mbc.7.2.193 
18. Berditchevski F. Complexes of tetraspanins with integrins: more than meets 
the eye. J Cell Sci (2001) 114:4143–51. 
19. Indig FE, Díaz-González F, Ginsberg MH. Analysis of the tetraspanin CD9-
integrin alphaIIbbeta3 (GPIIb-IIIa) complex in platelet membranes and 
transfected cells. Biochem J (1997) 327(Pt 1):291–8. doi:10.1042/bj3270291 
20. Longhurst CM, White MM, Wilkinson DA, Jennings LKA. CD9, alphaIIb-
beta3, integrin-associated protein, and GPIb/V/IX complex on the surface 
of human platelets is influenced by alphaIIbbeta3 conformational states. 
Eur J Biochem (1999) 263:104–11. doi:10.1046/j.1432-1327.1999.00467.x 
21. Reyes R, Monjas A, Yánez-Mó M, Cardeñes B, Morlino G, Gilsanz A, et al. 
Different states of integrin LFA-1 aggregation are controlled through its 
association with tetraspanin CD9. Biochim Biophys Acta (2015) 1853(10 Pt A): 
2464–80. doi:10.1016/j.bbamcr.2015.05.018 
22. Shibagaki N, Hanada K, Yamashita H, Shimada S, Hamada H. Over-
expression of CD82 on human T  cells enhances LFA-1/ICAM-1-mediated 
cell-cell adhesion: functional association between CD82 and LFA-1 in 
T cell activation. Eur J Immunol (1999) 29:4081–91. doi:10.1002/(SICI)1521- 
4141(199912)29:12<4081::AID-IMMU4081>3.0.CO;2-I 
23. VanCompernolle SE, Levy S, Todd SC. Anti-CD81 activates LFA-1 on T cells 
and promotes T cell-B cell collaboration. Eur J Immunol (2001) 31:823–31. 
doi:10.1002/1521-4141(200103)31:3<823::AID-IMMU823>3.0.CO;2-D 
24. Barreiro O, Zamai M, Yáñez-Mó M, Tejera E, López-Romero P, Monk PN, 
et  al. Endothelial adhesion receptors are recruited to adherent leukocytes 
by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol (2008) 
183:527–42. doi:10.1083/jcb.200805076 
25. Barreiro O, Yáñez-Mó M, Sala-Valdés M, Gutiérrez-López MD, Ovalle S, 
Higginbottom A, et  al. Endothelial tetraspanin microdomains regulate 
leukocyte firm adhesion during extravasation. Blood (2005) 105:2852–61. 
doi:10.1182/blood-2004-09-3606 
26. Schmidt DS, Klingbeil P, Schnolzer M, Zoller M. CD44 variant isoforms 
associate with tetraspanins and EpCAM. Exp Cell Res (2004) 297:329–47. 
doi:10.1016/j.yexcr.2004.02.023 
27. Le Naour F, Andre M, Boucheix C, Rubinstein E. Membrane microdomains 
and proteomics: lessons from tetraspanin microdomains and comparison 
with lipid rafts. Proteomics (2006) 6:6447–54. doi:10.1002/pmic.200600282 
28. Te Riet J, Helenius J, Strohmeyer N, Cambi A, Figdor CG, Müller DJ. Dynamic 
coupling of ALCAM to the actin cortex strengthens cell adhesion to CD6. 
J Cell Sci (2014) 127:1595–606. doi:10.1242/jcs.141077 
29. Gilsanz A, Sánchez-Martín L, Gutiérrez-López MD, Ovalle S, Machado-
Pineda Y, Reyes R, et  al. ALCAM/CD166 adhesive function is regulated 
by the tetraspanin CD9. Cell Mol Life Sci (2013) 70:475–93. doi:10.1007/
s00018-012-1132-0 
30. Slupsky JR, Seehafer JG, Tang SC, Masellis-Smith A, Shaw AR. Evidence 
that monoclonal antibodies against CD9 antigen induce specific association 
between CD9 and the platelet glycoprotein IIb-IIIa complex. J Biol Chem 
(1989) 264:12289–93. 
31. Boucheix C, Duc GH, Jasmin C, Rubinstein E. Tetraspanins and malignancy. 
Expert Rev Mol Med (2001) 3:1–17. doi:10.1017/S1462399401002381
32. Tarrant JM, Robb L, van Spriel AB, Wright MD. Tetraspanins: molecular 
organisers of the leukocyte surface. Trends Immunol (2003) 24:610–7. 
doi:10.1016/j.it.2003.09.011 
8Reyes et al. CD9 Regulates Immune Cell Adhesion
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 863
33. Toyo-oka K, Yashiro-Ohtani Y, Park CS, Tai XG, Miyake K, Hamaoka T, et al. 
Association of a tetraspanin CD9 with CD5 on the T  cell surface: role of 
particular transmembrane domains in the association. Int Immunol (1999) 
11:2043–52. doi:10.1093/intimm/11.12.2043 
34. Horváth G, Serru V, Clay D, Billard M, Boucheix C, Rubinstein E. CD19 is 
linked to the integrin-associated tetraspans CD9, CD81, and CD82. J Biol 
Chem (1998) 273:30537–43. doi:10.1074/jbc.273.46.30537 
35. Shi W, Fan H, Shum L, Derynck R. The tetraspanin CD9 associates with 
transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor 
activation and cell proliferation. J Cell Biol (2000) 148:591–602. doi:10.1083/
jcb.148.3.591 
36. Nakamura K, Iwamoto R, Mekada E. Membrane-anchored heparin-binding 
EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated 
protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at 
cell-cell contact sites. J Cell Biol (1995) 129:1691–705. doi:10.1083/jcb.129. 
6.1691 
37. Anzai N, Lee Y, Youn BS, Fukuda S, Kim YJ, Mantel C, et al. C-kit associated 
with the transmembrane 4 superfamily proteins constitutes a functionally 
distinct subunit in human hematopoietic progenitors. Blood (2002) 99: 
4413–21. doi:10.1182/blood.V99.12.4413 
38. Little KD, Hemler ME, Stipp CS. Dynamic regulation of a GPCR- 
tetraspanin-G protein complex on intact cells: central role of CD81 in 
facilitating GPR56-Galpha q/11 association. Mol Biol Cell (2004) 15:2375–87. 
doi:10.1091/mbc.E03-12-0886 
39. Yauch RL, Hemler ME. Specific interactions among transmembrane 4 super-
family (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J (2000) 
351(Pt 3):629–37. doi:10.1042/bj3510629 
40. Zhang XA, Bontrager AL, Stipp CS, Kraeft SK, Bazzoni G, Chen LB, et  al. 
Phosphorylation of a conserved integrin alpha 3 QPSXXE motif regulates 
signaling, motility, and cytoskeletal engagement. Mol Biol Cell (2001) 12: 
351–65. doi:10.1091/mbc.12.2.351 
41. Kaji K, Oda S, Shikano T, Ohnuki T, Uematsu Y, Sakagami J, et al. The gamete 
fusion process is defective in eggs of Cd9-deficient mice. Nat Genet (2000) 
24:279–82. doi:10.1038/73502 
42. Yanez-Mo M, Gutierrez-Lopez MD, Cabanas C. Functional interplay 
between tetraspanins and proteases. Cell Mol Life Sci (2011) 68:3323–35. 
doi:10.1007/s00018-011-0746-y 
43. Arduise C, Abache T, Li L, Billard M, Chabanon A, Ludwig A, et al. Tetras- 
panins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal 
growth factor. J Immunol (2008) 181:7002–13. doi:10.4049/jimmunol.181. 
10.7002 
44. Gutiérrez-López MD, Gilsanz A, Yáñez-Mó M, Ovalle S, Lafuente EM, 
Domínguez C, et  al. The sheddase activity of ADAM17/TACE is regulated 
by the tetraspanin CD9. Cell Mol Life Sci (2011) 68:3275–92. doi:10.1007/
s00018-011-0639-0 
45. Miao WM, Vasile E, Lane WS, Lawler J. CD36 associates with CD9 and 
integrins on human blood platelets. Blood (2001) 97:1689–96. doi:10.1182/
blood.V97.6.1689 
46. Okamoto T, Iwata S, Yamazaki H, Hatano R, Komiya E, Dang NH, et al. CD9 
negatively regulates CD26 expression and inhibits CD26-mediated enhance-
ment of invasive potential of malignant mesothelioma cells. PLoS One (2014) 
9:e86671. doi:10.1371/journal.pone.0086671 
47. Stipp CS, Kolesnikova TV, Hemler ME. EWI-2 is a major CD9 and CD81 
partner and member of a novel Ig protein subfamily. J Biol Chem (2001) 
276:40545–54. doi:10.1074/jbc.M107338200 
48. Charrin S, Le Naour F, Oualid M, Billard M, Faure G, Hanash SM, et  al. 
The major CD9 and CD81 molecular partner. Identification and character-
ization of the complexes. J Biol Chem (2001) 276:14329–37. doi:10.1074/jbc.
M011297200 
49. Pugholm LH, Bæk R, Søndergaard EK, Revenfeld AL, Jørgensen MM, 
Varming K. Phenotyping of leukocytes and leukocyte-derived extracellular 
vesicles. J Immunol Res (2016) 2016:6391264. doi:10.1155/2016/6391264 
50. Tohami T, Drucker L, Radnay J, Shapira H, Lishner M. Expression of 
tetraspanins in peripheral blood leukocytes: a comparison between normal 
and infectious conditions. Tissue Antigens (2004) 64:235–42. doi:10.1111/ 
j.1399-0039.2004.00271.x 
51. Zuidscherwoude M, Worah K, van der Schaaf A, Buschow SI, van Spriel AB. 
Differential expression of tetraspanin superfamily members in dendritic cell 
subsets. PLoS One (2017) 12:e0184317. doi:10.1371/journal.pone.0184317 
52. Gutierrez-Lopez MD, Ovalle S, Yanez-Mo M, Sanchez-Sanchez N, 
Rubinstein E, Olmo N, et al. A functionally relevant conformational epitope 
on the CD9 tetraspanin depends on the association with activated beta1 
integrin. J Biol Chem (2003) 278:208–18. doi:10.1074/jbc.M207805200 
53. Ovalle S, Gutiérrez-López MD, Monjas A, Cabañas C. Implication of the 
tetraspanin CD9 in the immune system and cancer. Inmunología (2007) 26: 
65–72. doi:10.1016/S0213-9626(07)70076-8 
54. Veenbergen S, van Spriel AB. Tetraspanins in the immune response against 
cancer. Immunol Lett (2011) 138:129–36. doi:10.1016/j.imlet.2011.03.010 
55. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et  al.  
The immunological synapse: a molecular machine controlling T cell activa-
tion. Science (1999) 285:221–7. doi:10.1126/science.285.5425.221 
56. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional 
segregation of supramolecular activation clusters in T  cells. Nature (1998) 
395:82–6. doi:10.1038/25764 
57. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling 
by cytoplasmic domain separation in integrins. Science (2003) 301:1720–5. 
doi:10.1126/science.1084174 
58. Kinashi T. Intracellular signalling controlling integrin activation in lympho-
cytes. Nat Rev Immunol (2005) 5:546–59. doi:10.1038/nri1646 
59. van Zanten TS, Cambi A, Koopman M, Joosten B, Figdor CG, Garcia- 
Parajo MF. Hotspots of GPI-anchored proteins and integrin nanoclusters 
function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A (2009) 
106:18557–62. doi:10.1073/pnas.0905217106 
60. Bakker GJ, Eich C, Torreno-Pina JA, Diez-Ahedo R, Perez-Samper G, 
van Zanten TS, et  al. Lateral mobility of individual integrin nanoclusters 
orchestrates the onset for leukocyte adhesion. Proc Natl Acad Sci U S A  
(2012) 109:4869–74. doi:10.1073/pnas.1116425109 
61. Lillemeier BF, Mörtelmaier MA, Forstner MB, Huppa JB, Groves JT, 
Davis MM. TCR and Lat are expressed on separate protein islands on T cell 
membranes and concatenate during activation. Nat Immunol (2010) 11:90–6. 
doi:10.1038/ni.1832 
62. Sherman E, Barr V, Manley S, Patterson G, Balagopalan L, Akpan I, et  al. 
Functional nanoscale organization of signaling molecules downstream 
of the T  cell antigen receptor. Immunity (2011) 35:705–20. doi:10.1016/j.
immuni.2011.10.004 
63. Hogg N, Patzak I, Willenbrock F. The insider’s guide to leukocyte integrin 
signalling and function. Nat Rev Immunol (2011) 11:416–26. doi:10.1038/
nri2986 
64. Rocha-Perugini V, González-Granado JM, Tejera E, López-Martín S, 
Yañez-Mó M, Sánchez-Madrid F. Tetraspanins CD9 and CD151 at the immune 
synapse support T-cell integrin signaling. Eur J Immunol (2014) 44:1967–75. 
doi:10.1002/eji.201344235 
65. van Kooyk Y, Figdor CG. Avidity regulation of integrins: the driving force 
in leukocyte adhesion. Curr Opin Cell Biol (2000) 12:542–7. doi:10.1016/
S0955-0674(00)00129-0 
66. Sala-Valdés M, Ursa A, Charrin S, Rubinstein E, Hemler ME, Sánchez- 
Madrid F, et al. EWI-2 and EWI-F link the tetraspanin web to the actin cyto-
skeleton through their direct association with ezrin-radixin-moesin proteins. 
J Biol Chem (2006) 281:19665–75. doi:10.1074/jbc.M602116200 
67. Mittelbrunn M, Molina A, Escribese MM, Yáñez-Mó M, Escudero E, Ursa A, 
et al. VLA-4 integrin concentrates at the peripheral supramolecular activation 
complex of the immune synapse and drives T helper 1 responses. Proc Natl 
Acad Sci U S A (2004) 101:11058–63. doi:10.1073/pnas.0307927101 
68. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell (2002) 
110:673–87. doi:10.1016/S0092-8674(02)00971-6 
69. Suzuki J, Yamasaki S, Wu J, Koretzky GA, Saito T. The actin cloud induced by 
LFA-1-mediated outside-in signals lowers the threshold for T-cell activation. 
Blood (2007) 109:168–75. doi:10.1182/blood-2005-12-020164 
70. Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, et al. Leuko-
cyte functional antigen 1 lowers T  cell activation thresholds and signaling 
through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol 
(2003) 4:1083–92. doi:10.1038/ni984 
71. Sato T, Tachibana K, Nojima Y, D’Avirro N, Morimoto C. Role of the VLA-4 
molecule in T cell costimulation. Identification of the tyrosine phosphoryla-
tion pattern induced by the ligation of VLA-4. J Immunol (1995) 155:2938–47. 
72. Verma NK, Kelleher D. Not just an adhesion molecule: LFA-1 contact tunes 
the T  lymphocyte program. J Immunol (2017) 199:1213–21. doi:10.4049/
jimmunol.1700495 
9Reyes et al. CD9 Regulates Immune Cell Adhesion
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 863
73. Mor A, Dustin ML, Philips MR. Small GTPases and LFA-1 reciprocally mod-
ulate adhesion and signaling. Immunol Rev (2007) 218:114–25. doi:10.1111/ 
j.1600-065X.2007.00538.x 
74. Dustin ML. Cell adhesion molecules and actin cytoskeleton at immune 
synapses and kinapses. Curr Opin Cell Biol (2007) 19:529–33. doi:10.1016/j.
ceb.2007.08.003 
75. Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, 
Figdor CG. Long-term engagement of CD6 and ALCAM is essential for 
T-cell proliferation induced by dendritic cells. Blood (2006) 107:3212–20. 
doi:10.1182/blood-2005-09-3881 
76. Gimferrer I, Calvo M, Mittelbrunn M, Farnós M, Sarrias MR, Enrich C, et al. 
Relevance of CD6-mediated interactions in T  cell activation and prolife- 
ration. J Immunol (2004) 173:2262–70. doi:10.4049/jimmunol.173.4.2262 
77. Hassan NJ, Barclay AN, Brown MH. Frontline: optimal T  cell activation 
requires the engagement of CD6 and CD166. Eur J Immunol (2004) 34:930–40. 
doi:10.1002/eji.200424856 
78. Tudor C, te Riet J, Eich C, Harkes R, Smisdom N, Bouhuijzen Wenger J, et al. 
Syntenin-1 and ezrin proteins link activated leukocyte cell adhesion molecule 
to the actin cytoskeleton. J Biol Chem (2014) 289:13445–60. doi:10.1074/jbc.
M113.546754 
79. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to 
specificity and diversity. Cell (1991) 67:1033–6. doi:10.1016/0092-8674(91) 
90279-8 
80. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte 
emigration: the multistep paradigm. Cell (1994) 76:301–14. doi:10.1016/ 
0092-8674(94)90337-9 
81. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity 
(2014) 41:694–707. doi:10.1016/j.immuni.2014.10.008 
82. Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, 
Tejedor R, et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin 
and ezrin in a novel endothelial docking structure for adherent leukocytes. 
J Cell Biol (2002) 157:1233–45. doi:10.1083/jcb.200112126 
83. Allingham MJ, van Buul JD, Burridge K. ICAM-1-mediated, Src- and Pyk2-
dependent vascular endothelial cadherin tyrosine phosphorylation is requi- 
red for leukocyte transendothelial migration. J Immunol (2007) 179:4053–64. 
doi:10.4049/jimmunol.179.6.4053 
84. Heemskerk N, van Rijssel J, van Buul JD. Rho-GTPase signaling in leukocyte 
extravasation: an endothelial point of view. Cell Adh Migr (2014) 8:67–75. 
doi:10.4161/cam.28244 
85. Franz J, Brinkmann BF, König M, Hüve J, Stock C, Ebnet K, et al. Nanoscale 
imaging reveals a tetraspanin-CD9 coordinated elevation of endothelial 
ICAM-1 clusters. PLoS One (2016) 11:e0146598. doi:10.1371/journal.pone. 
0146598 
86. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, et al. 
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking 
into the central nervous system. Nat Immunol (2008) 9:137–45. doi:10.1038/
ni1551 
87. Lyck R, Lécuyer MA, Abadier M, Wyss CB, Matti C, Rosito M, et al. ALCAM 
(CD166) is involved in extravasation of monocytes rather than T cells across 
the blood-brain barrier. J Cereb Blood Flow Metab (2017) 37:2894–909. 
doi:10.1177/0271678X16678639 
88. Lécuyer MA, Saint-Laurent O, Bourbonnière L, Larouche S, Larochelle C, 
Michel L, et  al. Dual role of ALCAM in neuroinflammation and blood-
brain barrier homeostasis. Proc Natl Acad Sci U S A (2017) 114:E524–33. 
doi:10.1073/pnas.1614336114 
89. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch 
to control inflammation and tissue regeneration. Trends Immunol (2011) 
32:380–7. doi:10.1016/j.it.2011.05.005 
90. Reiss K, Saftig P. The “a disintegrin and metalloprotease” (ADAM) family of 
sheddases: physiological and cellular functions. Semin Cell Dev Biol (2009) 
20:126–37. doi:10.1016/j.semcdb.2008.11.002 
91. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloprote- 
inases. Mol Aspects Med (2008) 29:258–89. doi:10.1016/j.mam.2008.08.001 
92. Hartmann M, Herrlich A, Herrlich P. Who decides when to cleave an ecto-
domain? Trends Biochem Sci (2013) 38:111–20. doi:10.1016/j.tibs.2012.12.002 
93. Grotzinger J, Lorenzen I, Dusterhoft S. Molecular insights into the multi-
layered regulation of ADAM17: the role of the extracellular region. Biochim 
Biophys Acta (2017) 1864:2088–95. doi:10.1016/j.bbamcr.2017.05.024 
94. Seipold L, Saftig P. The emerging role of tetraspanins in the proteolytic pro-
cessing of the amyloid precursor protein. Front Mol Neurosci (2016) 9:149. 
doi:10.3389/fnmol.2016.00149 
95. Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, Mauduit P, et al. 
TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote 
Notch activation in flies and mammals. J Cell Biol (2012) 199:481–96. 
doi:10.1083/jcb.201201133 
96. Saint-Pol J, Eschenbrenner E, Dornier E, Boucheix C, Charrin S, Rubinstein E. 
Regulation of the trafficking and the function of the metalloprotease 
ADAM10 by tetraspanins. Biochem Soc Trans (2017) 45:937–44. doi:10.1042/
BST20160296 
97. Matthews AL, Noy PJ, Reyat JS, Tomlinson MG. Regulation of A disintegrin 
and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: 
the emerging role of tetraspanins and rhomboids. Platelets (2017) 28:333–41. 
doi:10.1080/09537104.2016.1184751 
98. Tsukamoto S, Takeuchi M, Kawaguchi T, Togasaki E, Yamazaki A, Sugita Y, 
et al. Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in 
leukocytes. Exp Mol Med (2014) 46:e89. doi:10.1038/emm.2013.161 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Reyes, Cardeñes, Machado-Pineda and Cabañas. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
